Paratek Pharmaceuticals, Inc. - FORM 10-K - EX-32.1 - CERTIFICATION OF THE COMPANY'S CEO AND CFO PURSUANT TO SECTION 906 - March 30, 2011

Attached files

file filename
10-K - FORM 10-K - Paratek Pharmaceuticals, Inc.d10k.htm
EX-31.1 - CERTIFICATION OF THE COMPANY'S CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.dex311.htm
EX-31.2 - CERTIFICATION OF THE COMPANY'S CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.dex312.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Paratek Pharmaceuticals, Inc.dex231.htm
EX-10.32 - SECOND AMENDED AND RESTATED DIRECTOR COMPENSATION POLICY - Paratek Pharmaceuticals, Inc.dex1032.htm

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Transcept Pharmaceuticals, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the annual period ended December 31, 2010 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 30, 2011

 

/s/ Glenn A. Oclassen

Glenn A. Oclassen

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Thomas P. Soloway

Thomas P. Soloway

Senior Vice President, Operations and

Chief Financial Officer

(Principal Financial Officer)

Paratek Pharmaceuticals, Inc. Reports